CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...
Scientists had tried to treat diseases by editing genes since the 1990s, but the methods were cumbersome and didn’t pay off. Then in June 2012, the journal Science published a paper by two future ...
The FDA late last week set for December a groundbreaking decision on whether to grant its first-ever approval for a CRISPR-Cas9 gene-edited therapy—but the milestone so far doesn’t seem to be wowing ...
The launch of BIRSA 101 marks a major breakthrough in CRISPR gene-editing technology, positioning India to deliver affordable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback